← Search & browse all drugs
CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, PLAIN › ACE inhibitors, plain
benazepril
C09AA07
Forms & Strengths
- Oral Tablet: 5 mg
- Oral Tablet: 10 mg
- Oral Tablet: 20 mg
- Oral Tablet: 40 mg
Adult Dosing
- Hypertension (monotherapy, initial): 10 mg once daily
- Hypertension (maintenance): 20 to 40 mg daily administered in 1 or 2 divided doses
- Maximal daily dose: 80 mg
Pediatric Dosing
- Hypertension in children >= 6 years (initial): 0.2 mg/kg once daily
- Maximal pediatric initial dose: 10 mg once daily
- Maximal pediatric daily dose: 0.6 mg/kg (or up to 40 mg) once daily
Indications
- Management of hypertension
- Reduction of cardiovascular mortality and morbidity in high-risk patients (off-label/class effect)
Mechanism of Action
- Competitive inhibition of angiotensin-converting enzyme (ACE)
- Prevents conversion of angiotensin I to angiotensin II, a potent vasoconstrictor
- Decreases plasma angiotensin II, increases plasma renin activity, and decreases aldosterone secretion
Contraindications
- History of angioedema related to previous treatment with an ACE inhibitor
- Hereditary or idiopathic angioedema
- Concomitant use with aliskiren in patients with diabetes mellitus
- Co-administration with neprilysin inhibitors (e.g., sacubitril/valsartan)
Adverse Reactions
- Dizziness
- Headache
- Fatigue
- Cough (dry, persistent)
- Hyperkalemia
- Hypotension (especially orthostatic)
- Increased serum creatinine
- Angioedema (rare)
Drug Interactions
- Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium increase risk of hyperkalemia
- NSAIDs may diminish antihypertensive efficacy and increase risk of renal impairment
- Lithium toxicity risk increased due to decreased renal clearance
- Dual blockade of the renin-angiotensin system (e.g., ARBs, aliskiren) increases risk of hypotension, syncope, hyperkalemia, and renal dysfunction
Curated Content: Needs Vetting Before Put to Clinical Use